S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
Critical asset just had biggest fall on record (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
NASDAQ:VERU

Veru (VERU) Stock Price, News & Analysis

$0.55
-0.04 (-6.78%)
(As of 02/26/2024 ET)
Today's Range
$0.53
$0.59
50-Day Range
$0.37
$0.76
52-Week Range
$0.36
$4.20
Volume
1.42 million shs
Average Volume
2.12 million shs
Market Capitalization
$75.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Veru MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
899.6% Upside
$5.50 Price Target
Short Interest
Bearish
7.10% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.15mentions of Veru in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.43) to ($0.44) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.83 out of 5 stars

Medical Sector

831st out of 942 stocks

Pharmaceutical Preparations Industry

372nd out of 418 stocks


VERU stock logo

About Veru Stock (NASDAQ:VERU)

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

VERU Stock Price History

VERU Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
VERU Feb 2024 0.500 call
The 3 Best Penny Stocks to Buy in February 2024
VERU Apr 2024 3.000 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
VERU Feb 2024 1.000 call
VERU Jul 2024 2.000 call
Veru Inc. (NASDAQ:VERU) Q1 2024 Earnings Call Transcript
Q1 2024 Veru Inc Earnings Call
See More Headlines
Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/08/2023
Today
2/26/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
189
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.50
High Stock Price Target
$9.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+899.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-93,090,000.00
Net Margins
-571.20%
Pretax Margin
-568.26%

Debt

Sales & Book Value

Annual Sales
$16.30 million
Book Value
$0.20 per share

Miscellaneous

Free Float
118,075,000
Market Cap
$75.72 million
Optionable
Optionable
Beta
-0.29
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Mitchell S. Steiner F.A.C.S. (Age 63)
    M.D., Chairman, President & CEO
    Comp: $885.32k
  • Dr. Harry Fisch F.A.C.S. (Age 65)
    M.D., Vice Chairman & Chief Corporate Officer
  • Ms. Michele Greco (Age 65)
    CFO & Chief Administrative Officer
    Comp: $493.7k
  • Dr. Gary K. Barnette Ph.D. (Age 56)
    Chief Scientific Officer
    Comp: $676.27k
  • Mr. Samuel Fisch
    Executive Director of Investor Relations & Corporate Communications
  • Mr. Michael J. Purvis
    Executive VP, General Counsel & Corporate Strategy and Secretary
  • Mr. Kevin J. Gilbert CPA
    J.D., Executive Vice President of Corporate Development
  • Dr. Domingo Rodriguez M.D. (Age 62)
    Executive Vice President of Global Clinical Operations
  • Dr. Gary Bird Ph.D.
    Executive Vice President of Quality & Regulatory Affairs
  • Mr. Jason Davies
    Executive VP and GM of UK, Europe, EMEA, LATAM & ASPAC














VERU Stock Analysis - Frequently Asked Questions

Should I buy or sell Veru stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veru in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VERU shares.
View VERU analyst ratings
or view top-rated stocks.

What is Veru's stock price target for 2024?

3 equities research analysts have issued 12-month price objectives for Veru's shares. Their VERU share price targets range from $2.00 to $9.00. On average, they predict the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 899.6% from the stock's current price.
View analysts price targets for VERU
or view top-rated stocks among Wall Street analysts.

How have VERU shares performed in 2024?

Veru's stock was trading at $0.72 on January 1st, 2024. Since then, VERU shares have decreased by 23.6% and is now trading at $0.5502.
View the best growth stocks for 2024 here
.

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VERU earnings forecast
.

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) released its quarterly earnings data on Friday, December, 8th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04. The business earned $3.86 million during the quarter, compared to analyst estimates of $3.95 million. Veru had a negative net margin of 571.20% and a negative trailing twelve-month return on equity of 374.04%.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), Organigram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

Who are Veru's major shareholders?

Veru's stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (4.06%), Vanguard Group Inc. (3.42%), Octagon Capital Advisors LP (2.76%), AIGH Capital Management LLC (2.50%), Worth Venture Partners LLC (0.91%) and Potomac Capital Management Inc. (0.48%). Insiders that own company stock include Harry Fisch, Lucy Lu and Mario Eisenberger.
View institutional ownership trends
.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VERU) was last updated on 2/27/2024 by MarketBeat.com Staff